Atara Biotherapeutics (ATRA) vs Coherus Oncology (CHRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Atara Biotherapeutics (ATRA) has outperformed Coherus Oncology (CHRS) over the past year, losing 53.7% versus a loss of 68.1%. Over five years, CHRS leads with a -98.0% price change compared with -98.6% for ATRA. Atara Biotherapeutics is the larger company by market cap ($64.5 million vs $57.1 million), about 1.1 times the size, while Coherus Oncology is growing revenue faster (+59.8% vs -6.3%).
Coherus Oncology converts more of its revenue into profit, with a net margin of 398.4% versus 27.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATRA | CHRS |
|---|---|---|
| Share price | $6.33 | $0.3698 |
| Market cap | $64.49M | $57.15M |
| 1-day change | -0.16% | -4.47% |
| YTD return | -65.01% | -73.96% |
| 1-year return | -53.73% | -68.12% |
| 5-year return | -98.56% | -97.99% |
| Forward P/E | 3.96 | — |
| EPS (TTM) | $-1.12 | $-1.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $120.77M | $42.17M |
| Revenue growth (YoY) | -6.33% | +59.81% |
| Net income (latest FY) | $32.69M | $168.02M |
| Gross margin | — | 67.24% |
| Operating margin | 29.69% | -429.51% |
| Net margin | 27.07% | 398.43% |
| 52-week high | $19.15 | $2.62 |
| 52-week low | $3.92 | $0.3628 |
| Distance from 52-week high | -66.94% | -85.86% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +115.96% | +1995.73% |
| Average volume | 35.46K | 1.80M |
| Shares outstanding | 10.19M | 154.54M |
| Employees | 10 | 144 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATRA has outperformed CHRS by 14.4 percentage points over the past year.
- Coherus Oncology is more profitable, keeping 398.4 cents of every revenue dollar as net income versus 27.1 cents for Atara Biotherapeutics.
- Coherus Oncology grew revenue faster in its latest fiscal year (+59.81% vs -6.33%).
About Atara Biotherapeutics
ATRA stock →Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 10 employees
About Coherus Oncology
CHRS stock →Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 144 employees
ATRA vs CHRS FAQ
Which is bigger, Atara Biotherapeutics or Coherus Oncology?
Atara Biotherapeutics (ATRA) is larger, with a market capitalization of $64.49M compared with $57.15M for Coherus Oncology (CHRS).
Which stock has performed better over the past year, ATRA or CHRS?
ATRA returned -53.73% over the past 12 months, compared with -68.12% for CHRS (price return, excluding dividends). Past performance does not predict future results.
Are Atara Biotherapeutics and Coherus Oncology in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.